img

Global Familial Amyloid Polyneuropathy Therapeutic Market Research Report 2024

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Familial Amyloid Polyneuropathy Therapeutic Market Research Report 2024

Familial Amyloid Polyneuropathy (FAP) is a progressive, disabling and life-threatening polyneuropathy affecting the peripheral and autonomic nervous system. FAP is an autosomal transmission disorder which is usually due to a point mutation of the transthyretin (TTR) gene.The treatment of familial amyloid polyneuropathies (FAP) is complex and requires a neurological and cardiological multidisciplinary coverage. It includes specific treatments to control the progression of the systemic amyloidogenesis, the symptomatic treatment of the peripheral and autonomic neuropathy (digestive, urinary, sexual, postural hypotension) and the treatment of organs severely involved by amyloidosis (heart, eyes, kidneys).
According to Mr Accuracy reports new survey, global Familial Amyloid Polyneuropathy Therapeutic market is projected to reach US$ 2067.8 million in 2029, increasing from US$ 1387 million in 2022, with the CAGR of 5.9% during the period of 2024 to 2029.
The global familial amyloid polyneuropathy (FAP) therapeutic market refers to the market for treatments and therapies aimed at managing and treating familial amyloid polyneuropathy, also known as transthyretin amyloidosis (ATTR). FAP is a rare, progressive, and potentially fatal genetic disorder that affects the peripheral nerves and can lead to various symptoms and complications.
Here are some key points related to the global FAP therapeutic market
Market OverviewThe market for FAP therapeutics includes pharmaceutical drugs, gene therapies, and other treatment options aimed at managing the symptoms and halting the progression of the disease.
Disease-Modifying TherapiesThe development of disease-modifying therapies targeting the underlying cause of FAP is a significant focus in this market. These therapies aim to reduce the buildup of abnormal amyloid proteins in the peripheral nerves, which is a hallmark of FAP.
TTR StabilizersTTR (transthyretin) stabilizers are pharmacological agents that aim to stabilize the mutated TTR protein and prevent its misfolding and aggregation. Several TTR stabilizers have been approved or are under investigation for their efficacy in treating FAP.
RNA Interference (RNAi) TherapiesRNAi therapies, such as patisiran and inotersen, work by reducing the production of the TTR protein by interfering with the mRNA responsible for its synthesis. These therapies have shown promise in clinical trials and have been approved for the treatment of FAP in some regions.
Liver TransplantationIn some cases, liver transplantation may be considered as a treatment option for FAP. As the liver produces most of the circulating TTR, replacing the diseased liver with a healthy one can halt the production of mutant TTR and slow down the progression of the disease.
Geographic ConsiderationsThe global FAP therapeutic market is influenced by factors such as regional prevalence, healthcare infrastructure, regulatory environments, and reimbursement policies across different countries and regions.
Ongoing Research and DevelopmentThe FAP therapeutic market is dynamic, with ongoing research and development efforts focusing on novel therapies and treatment modalities. This includes gene therapies, small molecule inhibitors, and other approaches aimed at providing effective and targeted treatments for FAP.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Familial Amyloid Polyneuropathy Therapeutic market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.



By Company


Pfizer Inc.
Alnylam Pharmaceuticals Inc.
Ionis Pharmaceuticals Inc.
Corino Therapeutics Inc.
Proclara Biosciences
Arcturus Therapeutics Inc
Prothena Corporation
Eidos Therapeutics
FoldRx Pharmaceuticals
Akcea Therapeutics
GlaxoSmithKline (GSK)
Greenovation Biotech GmbH
Segment by Type
Inotersen
Tafamidis
Patisiran
Others

Segment by Application


Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Familial Amyloid Polyneuropathy Therapeutic report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Familial Amyloid Polyneuropathy Therapeutic Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Inotersen
1.2.3 Tafamidis
1.2.4 Patisiran
1.2.5 Others
1.3 Market by Application
1.3.1 Global Familial Amyloid Polyneuropathy Therapeutic Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Familial Amyloid Polyneuropathy Therapeutic Market Perspective (2018-2029)
2.2 Familial Amyloid Polyneuropathy Therapeutic Growth Trends by Region
2.2.1 Global Familial Amyloid Polyneuropathy Therapeutic Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Familial Amyloid Polyneuropathy Therapeutic Historic Market Size by Region (2018-2024)
2.2.3 Familial Amyloid Polyneuropathy Therapeutic Forecasted Market Size by Region (2024-2029)
2.3 Familial Amyloid Polyneuropathy Therapeutic Market Dynamics
2.3.1 Familial Amyloid Polyneuropathy Therapeutic Industry Trends
2.3.2 Familial Amyloid Polyneuropathy Therapeutic Market Drivers
2.3.3 Familial Amyloid Polyneuropathy Therapeutic Market Challenges
2.3.4 Familial Amyloid Polyneuropathy Therapeutic Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Familial Amyloid Polyneuropathy Therapeutic Players by Revenue
3.1.1 Global Top Familial Amyloid Polyneuropathy Therapeutic Players by Revenue (2018-2024)
3.1.2 Global Familial Amyloid Polyneuropathy Therapeutic Revenue Market Share by Players (2018-2024)
3.2 Global Familial Amyloid Polyneuropathy Therapeutic Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Familial Amyloid Polyneuropathy Therapeutic Revenue
3.4 Global Familial Amyloid Polyneuropathy Therapeutic Market Concentration Ratio
3.4.1 Global Familial Amyloid Polyneuropathy Therapeutic Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Familial Amyloid Polyneuropathy Therapeutic Revenue in 2022
3.5 Familial Amyloid Polyneuropathy Therapeutic Key Players Head office and Area Served
3.6 Key Players Familial Amyloid Polyneuropathy Therapeutic Product Solution and Service
3.7 Date of Enter into Familial Amyloid Polyneuropathy Therapeutic Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Familial Amyloid Polyneuropathy Therapeutic Breakdown Data by Type
4.1 Global Familial Amyloid Polyneuropathy Therapeutic Historic Market Size by Type (2018-2024)
4.2 Global Familial Amyloid Polyneuropathy Therapeutic Forecasted Market Size by Type (2024-2029)
5 Familial Amyloid Polyneuropathy Therapeutic Breakdown Data by Application
5.1 Global Familial Amyloid Polyneuropathy Therapeutic Historic Market Size by Application (2018-2024)
5.2 Global Familial Amyloid Polyneuropathy Therapeutic Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Familial Amyloid Polyneuropathy Therapeutic Market Size (2018-2029)
6.2 North America Familial Amyloid Polyneuropathy Therapeutic Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Familial Amyloid Polyneuropathy Therapeutic Market Size by Country (2018-2024)
6.4 North America Familial Amyloid Polyneuropathy Therapeutic Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Familial Amyloid Polyneuropathy Therapeutic Market Size (2018-2029)
7.2 Europe Familial Amyloid Polyneuropathy Therapeutic Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Familial Amyloid Polyneuropathy Therapeutic Market Size by Country (2018-2024)
7.4 Europe Familial Amyloid Polyneuropathy Therapeutic Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Familial Amyloid Polyneuropathy Therapeutic Market Size (2018-2029)
8.2 Asia-Pacific Familial Amyloid Polyneuropathy Therapeutic Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Familial Amyloid Polyneuropathy Therapeutic Market Size by Region (2018-2024)
8.4 Asia-Pacific Familial Amyloid Polyneuropathy Therapeutic Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Familial Amyloid Polyneuropathy Therapeutic Market Size (2018-2029)
9.2 Latin America Familial Amyloid Polyneuropathy Therapeutic Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Familial Amyloid Polyneuropathy Therapeutic Market Size by Country (2018-2024)
9.4 Latin America Familial Amyloid Polyneuropathy Therapeutic Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Familial Amyloid Polyneuropathy Therapeutic Market Size (2018-2029)
10.2 Middle East & Africa Familial Amyloid Polyneuropathy Therapeutic Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Familial Amyloid Polyneuropathy Therapeutic Market Size by Country (2018-2024)
10.4 Middle East & Africa Familial Amyloid Polyneuropathy Therapeutic Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer Inc.
11.1.1 Pfizer Inc. Company Detail
11.1.2 Pfizer Inc. Business Overview
11.1.3 Pfizer Inc. Familial Amyloid Polyneuropathy Therapeutic Introduction
11.1.4 Pfizer Inc. Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2024)
11.1.5 Pfizer Inc. Recent Development
11.2 Alnylam Pharmaceuticals Inc.
11.2.1 Alnylam Pharmaceuticals Inc. Company Detail
11.2.2 Alnylam Pharmaceuticals Inc. Business Overview
11.2.3 Alnylam Pharmaceuticals Inc. Familial Amyloid Polyneuropathy Therapeutic Introduction
11.2.4 Alnylam Pharmaceuticals Inc. Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2024)
11.2.5 Alnylam Pharmaceuticals Inc. Recent Development
11.3 Ionis Pharmaceuticals Inc.
11.3.1 Ionis Pharmaceuticals Inc. Company Detail
11.3.2 Ionis Pharmaceuticals Inc. Business Overview
11.3.3 Ionis Pharmaceuticals Inc. Familial Amyloid Polyneuropathy Therapeutic Introduction
11.3.4 Ionis Pharmaceuticals Inc. Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2024)
11.3.5 Ionis Pharmaceuticals Inc. Recent Development
11.4 Corino Therapeutics Inc.
11.4.1 Corino Therapeutics Inc. Company Detail
11.4.2 Corino Therapeutics Inc. Business Overview
11.4.3 Corino Therapeutics Inc. Familial Amyloid Polyneuropathy Therapeutic Introduction
11.4.4 Corino Therapeutics Inc. Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2024)
11.4.5 Corino Therapeutics Inc. Recent Development
11.5 Proclara Biosciences
11.5.1 Proclara Biosciences Company Detail
11.5.2 Proclara Biosciences Business Overview
11.5.3 Proclara Biosciences Familial Amyloid Polyneuropathy Therapeutic Introduction
11.5.4 Proclara Biosciences Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2024)
11.5.5 Proclara Biosciences Recent Development
11.6 Arcturus Therapeutics Inc
11.6.1 Arcturus Therapeutics Inc Company Detail
11.6.2 Arcturus Therapeutics Inc Business Overview
11.6.3 Arcturus Therapeutics Inc Familial Amyloid Polyneuropathy Therapeutic Introduction
11.6.4 Arcturus Therapeutics Inc Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2024)
11.6.5 Arcturus Therapeutics Inc Recent Development
11.7 Prothena Corporation
11.7.1 Prothena Corporation Company Detail
11.7.2 Prothena Corporation Business Overview
11.7.3 Prothena Corporation Familial Amyloid Polyneuropathy Therapeutic Introduction
11.7.4 Prothena Corporation Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2024)
11.7.5 Prothena Corporation Recent Development
11.8 Eidos Therapeutics
11.8.1 Eidos Therapeutics Company Detail
11.8.2 Eidos Therapeutics Business Overview
11.8.3 Eidos Therapeutics Familial Amyloid Polyneuropathy Therapeutic Introduction
11.8.4 Eidos Therapeutics Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2024)
11.8.5 Eidos Therapeutics Recent Development
11.9 FoldRx Pharmaceuticals
11.9.1 FoldRx Pharmaceuticals Company Detail
11.9.2 FoldRx Pharmaceuticals Business Overview
11.9.3 FoldRx Pharmaceuticals Familial Amyloid Polyneuropathy Therapeutic Introduction
11.9.4 FoldRx Pharmaceuticals Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2024)
11.9.5 FoldRx Pharmaceuticals Recent Development
11.10 Akcea Therapeutics
11.10.1 Akcea Therapeutics Company Detail
11.10.2 Akcea Therapeutics Business Overview
11.10.3 Akcea Therapeutics Familial Amyloid Polyneuropathy Therapeutic Introduction
11.10.4 Akcea Therapeutics Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2024)
11.10.5 Akcea Therapeutics Recent Development
11.11 GlaxoSmithKline (GSK)
11.11.1 GlaxoSmithKline (GSK) Company Detail
11.11.2 GlaxoSmithKline (GSK) Business Overview
11.11.3 GlaxoSmithKline (GSK) Familial Amyloid Polyneuropathy Therapeutic Introduction
11.11.4 GlaxoSmithKline (GSK) Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2024)
11.11.5 GlaxoSmithKline (GSK) Recent Development
11.12 Greenovation Biotech GmbH
11.12.1 Greenovation Biotech GmbH Company Detail
11.12.2 Greenovation Biotech GmbH Business Overview
11.12.3 Greenovation Biotech GmbH Familial Amyloid Polyneuropathy Therapeutic Introduction
11.12.4 Greenovation Biotech GmbH Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2024)
11.12.5 Greenovation Biotech GmbH Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Familial Amyloid Polyneuropathy Therapeutic Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029
Table 2. Key Players of Inotersen
Table 3. Key Players of Tafamidis
Table 4. Key Players of Patisiran
Table 5. Key Players of Others
Table 6. Global Familial Amyloid Polyneuropathy Therapeutic Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029
Table 7. Global Familial Amyloid Polyneuropathy Therapeutic Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 8. Global Familial Amyloid Polyneuropathy Therapeutic Market Size by Region (2018-2024) & (US$ Million)
Table 9. Global Familial Amyloid Polyneuropathy Therapeutic Market Share by Region (2018-2024)
Table 10. Global Familial Amyloid Polyneuropathy Therapeutic Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 11. Global Familial Amyloid Polyneuropathy Therapeutic Market Share by Region (2024-2029)
Table 12. Familial Amyloid Polyneuropathy Therapeutic Market Trends
Table 13. Familial Amyloid Polyneuropathy Therapeutic Market Drivers
Table 14. Familial Amyloid Polyneuropathy Therapeutic Market Challenges
Table 15. Familial Amyloid Polyneuropathy Therapeutic Market Restraints
Table 16. Global Familial Amyloid Polyneuropathy Therapeutic Revenue by Players (2018-2024) & (US$ Million)
Table 17. Global Familial Amyloid Polyneuropathy Therapeutic Market Share by Players (2018-2024)
Table 18. Global Top Familial Amyloid Polyneuropathy Therapeutic Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Familial Amyloid Polyneuropathy Therapeutic as of 2022)
Table 19. Ranking of Global Top Familial Amyloid Polyneuropathy Therapeutic Companies by Revenue (US$ Million) in 2022
Table 20. Global 5 Largest Players Market Share by Familial Amyloid Polyneuropathy Therapeutic Revenue (CR5 and HHI) & (2018-2024)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Familial Amyloid Polyneuropathy Therapeutic Product Solution and Service
Table 23. Date of Enter into Familial Amyloid Polyneuropathy Therapeutic Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Familial Amyloid Polyneuropathy Therapeutic Market Size by Type (2018-2024) & (US$ Million)
Table 26. Global Familial Amyloid Polyneuropathy Therapeutic Revenue Market Share by Type (2018-2024)
Table 27. Global Familial Amyloid Polyneuropathy Therapeutic Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 28. Global Familial Amyloid Polyneuropathy Therapeutic Revenue Market Share by Type (2024-2029)
Table 29. Global Familial Amyloid Polyneuropathy Therapeutic Market Size by Application (2018-2024) & (US$ Million)
Table 30. Global Familial Amyloid Polyneuropathy Therapeutic Revenue Market Share by Application (2018-2024)
Table 31. Global Familial Amyloid Polyneuropathy Therapeutic Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 32. Global Familial Amyloid Polyneuropathy Therapeutic Revenue Market Share by Application (2024-2029)
Table 33. North America Familial Amyloid Polyneuropathy Therapeutic Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 34. North America Familial Amyloid Polyneuropathy Therapeutic Market Size by Country (2018-2024) & (US$ Million)
Table 35. North America Familial Amyloid Polyneuropathy Therapeutic Market Size by Country (2024-2029) & (US$ Million)
Table 36. Europe Familial Amyloid Polyneuropathy Therapeutic Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 37. Europe Familial Amyloid Polyneuropathy Therapeutic Market Size by Country (2018-2024) & (US$ Million)
Table 38. Europe Familial Amyloid Polyneuropathy Therapeutic Market Size by Country (2024-2029) & (US$ Million)
Table 39. Asia-Pacific Familial Amyloid Polyneuropathy Therapeutic Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029
Table 40. Asia-Pacific Familial Amyloid Polyneuropathy Therapeutic Market Size by Region (2018-2024) & (US$ Million)
Table 41. Asia-Pacific Familial Amyloid Polyneuropathy Therapeutic Market Size by Region (2024-2029) & (US$ Million)
Table 42. Latin America Familial Amyloid Polyneuropathy Therapeutic Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 43. Latin America Familial Amyloid Polyneuropathy Therapeutic Market Size by Country (2018-2024) & (US$ Million)
Table 44. Latin America Familial Amyloid Polyneuropathy Therapeutic Market Size by Country (2024-2029) & (US$ Million)
Table 45. Middle East & Africa Familial Amyloid Polyneuropathy Therapeutic Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 46. Middle East & Africa Familial Amyloid Polyneuropathy Therapeutic Market Size by Country (2018-2024) & (US$ Million)
Table 47. Middle East & Africa Familial Amyloid Polyneuropathy Therapeutic Market Size by Country (2024-2029) & (US$ Million)
Table 48. Pfizer Inc. Company Detail
Table 49. Pfizer Inc. Business Overview
Table 50. Pfizer Inc. Familial Amyloid Polyneuropathy Therapeutic Product
Table 51. Pfizer Inc. Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2024) & (US$ Million)
Table 52. Pfizer Inc. Recent Development
Table 53. Alnylam Pharmaceuticals Inc. Company Detail
Table 54. Alnylam Pharmaceuticals Inc. Business Overview
Table 55. Alnylam Pharmaceuticals Inc. Familial Amyloid Polyneuropathy Therapeutic Product
Table 56. Alnylam Pharmaceuticals Inc. Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2024) & (US$ Million)
Table 57. Alnylam Pharmaceuticals Inc. Recent Development
Table 58. Ionis Pharmaceuticals Inc. Company Detail
Table 59. Ionis Pharmaceuticals Inc. Business Overview
Table 60. Ionis Pharmaceuticals Inc. Familial Amyloid Polyneuropathy Therapeutic Product
Table 61. Ionis Pharmaceuticals Inc. Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2024) & (US$ Million)
Table 62. Ionis Pharmaceuticals Inc. Recent Development
Table 63. Corino Therapeutics Inc. Company Detail
Table 64. Corino Therapeutics Inc. Business Overview
Table 65. Corino Therapeutics Inc. Familial Amyloid Polyneuropathy Therapeutic Product
Table 66. Corino Therapeutics Inc. Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2024) & (US$ Million)
Table 67. Corino Therapeutics Inc. Recent Development
Table 68. Proclara Biosciences Company Detail
Table 69. Proclara Biosciences Business Overview
Table 70. Proclara Biosciences Familial Amyloid Polyneuropathy Therapeutic Product
Table 71. Proclara Biosciences Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2024) & (US$ Million)
Table 72. Proclara Biosciences Recent Development
Table 73. Arcturus Therapeutics Inc Company Detail
Table 74. Arcturus Therapeutics Inc Business Overview
Table 75. Arcturus Therapeutics Inc Familial Amyloid Polyneuropathy Therapeutic Product
Table 76. Arcturus Therapeutics Inc Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2024) & (US$ Million)
Table 77. Arcturus Therapeutics Inc Recent Development
Table 78. Prothena Corporation Company Detail
Table 79. Prothena Corporation Business Overview
Table 80. Prothena Corporation Familial Amyloid Polyneuropathy Therapeutic Product
Table 81. Prothena Corporation Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2024) & (US$ Million)
Table 82. Prothena Corporation Recent Development
Table 83. Eidos Therapeutics Company Detail
Table 84. Eidos Therapeutics Business Overview
Table 85. Eidos Therapeutics Familial Amyloid Polyneuropathy Therapeutic Product
Table 86. Eidos Therapeutics Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2024) & (US$ Million)
Table 87. Eidos Therapeutics Recent Development
Table 88. FoldRx Pharmaceuticals Company Detail
Table 89. FoldRx Pharmaceuticals Business Overview
Table 90. FoldRx Pharmaceuticals Familial Amyloid Polyneuropathy Therapeutic Product
Table 91. FoldRx Pharmaceuticals Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2024) & (US$ Million)
Table 92. FoldRx Pharmaceuticals Recent Development
Table 93. Akcea Therapeutics Company Detail
Table 94. Akcea Therapeutics Business Overview
Table 95. Akcea Therapeutics Familial Amyloid Polyneuropathy Therapeutic Product
Table 96. Akcea Therapeutics Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2024) & (US$ Million)
Table 97. Akcea Therapeutics Recent Development
Table 98. GlaxoSmithKline (GSK) Company Detail
Table 99. GlaxoSmithKline (GSK) Business Overview
Table 100. GlaxoSmithKline (GSK) Familial Amyloid Polyneuropathy Therapeutic Product
Table 101. GlaxoSmithKline (GSK) Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2024) & (US$ Million)
Table 102. GlaxoSmithKline (GSK) Recent Development
Table 103. Greenovation Biotech GmbH Company Detail
Table 104. Greenovation Biotech GmbH Business Overview
Table 105. Greenovation Biotech GmbH Familial Amyloid Polyneuropathy Therapeutic Product
Table 106. Greenovation Biotech GmbH Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2024) & (US$ Million)
Table 107. Greenovation Biotech GmbH Recent Development
Table 108. Research Programs/Design for This Report
Table 109. Key Data Information from Secondary Sources
Table 110. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Familial Amyloid Polyneuropathy Therapeutic Market Size Comparison by Type (2024-2029) & (US$ Million)
Figure 2. Global Familial Amyloid Polyneuropathy Therapeutic Market Share by Type: 2022 VS 2029
Figure 3. Inotersen Features
Figure 4. Tafamidis Features
Figure 5. Patisiran Features
Figure 6. Others Features
Figure 7. Global Familial Amyloid Polyneuropathy Therapeutic Market Size Comparison by Application (2024-2029) & (US$ Million)
Figure 8. Global Familial Amyloid Polyneuropathy Therapeutic Market Share by Application: 2022 VS 2029
Figure 9. Hospital Pharmacies Case Studies
Figure 10. Retail Pharmacies Case Studies
Figure 11. Online Pharmacies Case Studies
Figure 12. Others Case Studies
Figure 13. Familial Amyloid Polyneuropathy Therapeutic Report Years Considered
Figure 14. Global Familial Amyloid Polyneuropathy Therapeutic Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 15. Global Familial Amyloid Polyneuropathy Therapeutic Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 16. Global Familial Amyloid Polyneuropathy Therapeutic Market Share by Region: 2022 VS 2029
Figure 17. Global Familial Amyloid Polyneuropathy Therapeutic Market Share by Players in 2022
Figure 18. Global Top Familial Amyloid Polyneuropathy Therapeutic Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Familial Amyloid Polyneuropathy Therapeutic as of 2022)
Figure 19. The Top 10 and 5 Players Market Share by Familial Amyloid Polyneuropathy Therapeutic Revenue in 2022
Figure 20. North America Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 21. North America Familial Amyloid Polyneuropathy Therapeutic Market Share by Country (2018-2029)
Figure 22. United States Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 23. Canada Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 24. Europe Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 25. Europe Familial Amyloid Polyneuropathy Therapeutic Market Share by Country (2018-2029)
Figure 26. Germany Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 27. France Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 28. U.K. Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 29. Italy Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. Russia Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. Nordic Countries Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. Asia-Pacific Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. Asia-Pacific Familial Amyloid Polyneuropathy Therapeutic Market Share by Region (2018-2029)
Figure 34. China Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. Japan Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. South Korea Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 37. Southeast Asia Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 38. India Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 39. Australia Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 40. Latin America Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 41. Latin America Familial Amyloid Polyneuropathy Therapeutic Market Share by Country (2018-2029)
Figure 42. Mexico Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 43. Brazil Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. Middle East & Africa Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. Middle East & Africa Familial Amyloid Polyneuropathy Therapeutic Market Share by Country (2018-2029)
Figure 46. Turkey Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 47. Saudi Arabia Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 48. Pfizer Inc. Revenue Growth Rate in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2024)
Figure 49. Alnylam Pharmaceuticals Inc. Revenue Growth Rate in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2024)
Figure 50. Ionis Pharmaceuticals Inc. Revenue Growth Rate in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2024)
Figure 51. Corino Therapeutics Inc. Revenue Growth Rate in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2024)
Figure 52. Proclara Biosciences Revenue Growth Rate in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2024)
Figure 53. Arcturus Therapeutics Inc Revenue Growth Rate in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2024)
Figure 54. Prothena Corporation Revenue Growth Rate in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2024)
Figure 55. Eidos Therapeutics Revenue Growth Rate in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2024)
Figure 56. FoldRx Pharmaceuticals Revenue Growth Rate in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2024)
Figure 57. Akcea Therapeutics Revenue Growth Rate in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2024)
Figure 58. GlaxoSmithKline (GSK) Revenue Growth Rate in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2024)
Figure 59. Greenovation Biotech GmbH Revenue Growth Rate in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2024)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries